EE9900050A - Rho kinaasi inhibiitorit sisaldav farmatseutiline aine - Google Patents

Rho kinaasi inhibiitorit sisaldav farmatseutiline aine

Info

Publication number
EE9900050A
EE9900050A EEP199900050A EE9900050A EE9900050A EE 9900050 A EE9900050 A EE 9900050A EE P199900050 A EEP199900050 A EE P199900050A EE 9900050 A EE9900050 A EE 9900050A EE 9900050 A EE9900050 A EE 9900050A
Authority
EE
Estonia
Prior art keywords
therapeutic agent
agent
kinase inhibitor
rho kinase
pharmaceutical agent
Prior art date
Application number
EEP199900050A
Other languages
English (en)
Inventor
Uehata Masayoshi
Ono Takashi
Yamagami Keiji
Satoh Hiroyuki
Kawahara Toshio
Original Assignee
Yoshitomi Pharmaceutical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16622116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9900050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yoshitomi Pharmaceutical Industries, Ltd. filed Critical Yoshitomi Pharmaceutical Industries, Ltd.
Publication of EE9900050A publication Critical patent/EE9900050A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP199900050A 1996-08-12 1997-08-08 Rho kinaasi inhibiitorit sisaldav farmatseutiline aine EE9900050A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21240996 1996-08-12
PCT/JP1997/002793 WO1998006433A1 (en) 1996-08-12 1997-08-08 MEDICINES COMPRISING Rho KINASE INHIBITOR

Publications (1)

Publication Number Publication Date
EE9900050A true EE9900050A (et) 1999-08-16

Family

ID=16622116

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900050A EE9900050A (et) 1996-08-12 1997-08-08 Rho kinaasi inhibiitorit sisaldav farmatseutiline aine

Country Status (25)

Country Link
US (3) US6218410B1 (et)
EP (1) EP0956865B2 (et)
JP (1) JP3669711B2 (et)
KR (2) KR100595740B1 (et)
CN (1) CN100389828C (et)
AT (1) ATE359822T1 (et)
AU (1) AU738620B2 (et)
BG (4) BG107195A (et)
BR (1) BR9711154A (et)
CA (1) CA2263425C (et)
CZ (1) CZ301044B6 (et)
DE (1) DE69737631T3 (et)
DK (1) DK0956865T4 (et)
EE (1) EE9900050A (et)
ES (1) ES2286834T5 (et)
HU (1) HU229864B1 (et)
IL (1) IL128456A0 (et)
IS (1) IS4973A (et)
NO (1) NO990622L (et)
NZ (2) NZ513800A (et)
PL (1) PL331561A1 (et)
PT (1) PT956865E (et)
RU (3) RU2206321C2 (et)
SI (1) SI0956865T2 (et)
WO (1) WO1998006433A1 (et)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
EP1074545A4 (en) * 1998-04-23 2001-08-22 Hiroyoshi Hidaka ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT
CA2307285C (en) 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
WO2000057914A1 (en) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
WO2000057913A1 (en) * 1999-03-25 2000-10-05 Welfide Corporation Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
AU3987800A (en) * 1999-04-22 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for angiostenosis
EP1177796B1 (en) 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
AU7451200A (en) * 1999-09-29 2001-04-30 Mitsubishi Pharma Corporation Analgesics
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001068607A1 (en) * 2000-03-16 2001-09-20 Mitsubishi Pharma Corporation Amide compounds and use thereof
AU2001236006A1 (en) 2000-03-31 2001-10-15 Mitsubishi Pharma Corporation Preventives/remedies for kidney diseases
CN100548375C (zh) 2000-06-23 2009-10-14 田边三菱制药株式会社 抗肿瘤作用增效剂
JP2004509876A (ja) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
EP1318985A2 (en) * 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
JP4582561B2 (ja) * 2000-10-23 2010-11-17 旭化成ファーマ株式会社 移植による血管病変の発生抑制剤
JP2002139493A (ja) * 2000-11-01 2002-05-17 Sumitomo Pharmaceut Co Ltd 新規なハイスループット・スクリーニング方法
CA2325842C (en) 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
US20020132832A1 (en) * 2001-01-05 2002-09-19 Mills Thomas M. Treatment of erectile dysfunction
JP2002226375A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 線維化予防、治療剤
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
UY27224A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
US7109208B2 (en) * 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE10153605A1 (de) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
WO2003047591A1 (fr) * 2001-11-30 2003-06-12 Asahi Kasei Pharma Corporation Medicaments contre l'hypertension arterielle pulmonaire primitive
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
CN1681525A (zh) * 2002-07-12 2005-10-12 曹义海 一种抑制血管渗漏和组织水肿的方法
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
EP1541559A4 (en) * 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
US20040105860A1 (en) * 2002-08-01 2004-06-03 Losordo Douglas W. Cell modulation using a cytoskeletal protein
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
AU2003264427A1 (en) 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
ATE525111T1 (de) * 2003-04-18 2011-10-15 Senju Pharma Co 2-chloro-6,7-dimethoxy-n-5 ä5-(1)h- indazolylüquinazolin-4-amin, n-(1-benzyl-4- piperidinyl)-1h-indazol-5-amin dihydrochlorid, 4- ä2-(2,3,4,5,6-
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20110098232A1 (en) * 2003-05-30 2011-04-28 Zeilig Charles E Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
WO2005017161A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7371850B1 (en) * 2003-08-20 2008-05-13 Myriad Genetics, Inc. Method and composition for reducing expression of ROCK-II
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
WO2005056024A1 (en) * 2003-12-05 2005-06-23 Children's Hospital Medical Center Methods of enhancing stem cell engraftment
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
CA2548146A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
CA2556589A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
WO2005094824A1 (en) * 2004-03-25 2005-10-13 East Carolina University Methods of enhancing cancer therapy by protecting nerve cells
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
AU2005229015C1 (en) 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
US7485654B2 (en) * 2004-06-03 2009-02-03 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879100B1 (fr) 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
MX2007007797A (es) * 2004-12-27 2007-08-23 Alcon Inc Analogo de aminopirazina para tratar glaucoma y otras enfermedades mediadas por rho cinasa.
WO2006088088A1 (ja) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Ｒｏｃｋ阻害剤を含有する疼痛治療剤
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
RS52241B (sr) 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP4832051B2 (ja) * 2005-10-21 2011-12-07 学校法人順天堂 半月体形成性腎病変治療剤
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
MX2008008328A (es) * 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2008152065A (ru) 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
BRPI0714782A2 (pt) 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2439057C2 (ru) * 2006-11-28 2012-01-10 Эмкьюар Фармасьютикалз Лимитед Способ получения противорвотного препарата
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
BRPI0720986A2 (pt) 2006-12-27 2014-03-11 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
MY148902A (en) 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2008089351A1 (en) * 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
KR101566171B1 (ko) 2007-03-09 2015-11-06 삼성전자 주식회사 디지털 저작권 관리 방법 및 장치
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009028631A1 (ja) * 2007-08-29 2009-03-05 Senju Pharmaceutical Co., Ltd. 角膜内皮細胞接着促進剤
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
CA2728137C (en) 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
MY153756A (en) 2008-06-24 2015-03-13 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
MY153615A (en) 2008-06-24 2015-02-27 Sanofi Aventis 6-substituted isoquinolines and isoquinolinones
KR20110042054A (ko) 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 축성 근시의 예방 또는 치료제
US20110166161A1 (en) * 2008-09-18 2011-07-07 Astellas Pharma Inc. Heterocyclic carboxamide compounds
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
CA2777720C (en) 2009-10-16 2020-10-06 The Scripps Research Institute Induction of pluripotent cells
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
CN102188697B (zh) * 2010-03-03 2014-11-05 中国医学科学院药物研究所 重组人Rho激酶在制备药物中的应用
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2655601A4 (en) 2010-12-22 2014-09-10 Fate Therapeutics Inc CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
EP2846834A1 (en) * 2012-05-08 2015-03-18 Syddansk Universitet Anabolic compounds for treating and preventing bone loss diseases
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
JP5557408B1 (ja) 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
SG11201509982UA (et) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
CA2941004A1 (en) 2014-03-04 2015-09-11 Peter Flynn Improved reprogramming methods and cell culture platforms
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
CN107075469A (zh) 2014-06-27 2017-08-18 加利福尼亚大学董事会 培养的哺乳动物角膜缘干细胞、其产生方法和其用途
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CN107847584B (zh) 2015-02-09 2022-01-25 纪念斯隆凯特琳癌症中心 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US10167253B2 (en) 2015-06-24 2019-01-01 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
EP3383911B1 (en) 2015-12-02 2021-01-20 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111116555B (zh) 2018-10-30 2023-06-02 北京盈科瑞创新药物研究有限公司 一种Rho激酶抑制剂及其制备方法和应用
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
US12473284B2 (en) * 2019-12-30 2025-11-18 Memorial Sloan Kettering Cancer Center Small molecule inhibitors of ULK1
JP2023522784A (ja) 2020-04-27 2023-05-31 ノバルティス アーゲー 眼細胞療法のための方法及び組成物
CN111707831A (zh) * 2020-07-16 2020-09-25 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断sle以及评价sle病情中的应用
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
CN113262226B (zh) * 2021-04-19 2023-05-16 杭州市第一人民医院 利舒地尔在制备细菌感染治疗药物中的应用
CN118159645A (zh) 2021-10-18 2024-06-07 埃维亚生命科学有限公司 组合物及使用其治疗肝纤维化的方法
EP4419120A2 (en) 2021-10-22 2024-08-28 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
EP4472733A1 (en) 2022-01-31 2024-12-11 BYOMass Inc. Myeloproliferative conditions
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58121278A (ja) 1982-01-12 1983-07-19 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4456757A (en) † 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPH0227992B2 (ja) 1982-01-14 1990-06-20 Asahi Kasei Kogyo Kk Isokinorinsuruhonirukagobutsu
JPS57200366A (en) * 1981-06-01 1982-12-08 Asahi Chem Ind Co Ltd Isoquinoline compound
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
JPS6081168A (ja) 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd アミジン誘導体
JPS61227581A (ja) 1985-04-02 1986-10-09 Asahi Chem Ind Co Ltd 血管拡張剤
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPS61152658A (ja) 1984-12-27 1986-07-11 Asahi Chem Ind Co Ltd 置換されたイソキノリンスルホンアミド誘導体
EP0187371B1 (en) † 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPH062741B2 (ja) 1985-10-29 1994-01-12 旭化成工業株式会社 ２級のイソキノリンスルホンアミド誘導体
JP2770497B2 (ja) * 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途
WO1990005723A1 (fr) † 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
JP2720348B2 (ja) * 1989-03-30 1998-03-04 旭化成工業株式会社 脳細胞機能障害改善剤
JP3408546B2 (ja) * 1991-02-19 2003-05-19 旭化成株式会社 抗喘息剤
JP2864489B2 (ja) * 1991-02-27 1999-03-03 吉富製薬株式会社 喘息治療剤
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
JP3275389B2 (ja) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 ４−アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JPH05273821A (ja) 1992-03-24 1993-10-22 Nippon Steel Corp 静電画像形成装置
JP3265695B2 (ja) * 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 ４−置換アミノ（アルキル）シクロヘキサン−１−カルボン酸アミド化合物
JP2893029B2 (ja) 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
JP3218356B2 (ja) 1993-03-31 2001-10-15 ヤンマー農機株式会社 管理機
JPH06289679A (ja) * 1993-04-01 1994-10-18 Hitachi Metals Ltd 画像形成方法
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
DE4323295C1 (de) * 1993-07-12 1995-02-09 Manfred R Dr Hamm Dosiervorrichtung
JPH0741424A (ja) * 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd 抗炎症剤
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho

Also Published As

Publication number Publication date
IL128456A0 (en) 2000-01-31
JP3669711B2 (ja) 2005-07-13
CN1233188A (zh) 1999-10-27
SI0956865T1 (sl) 2007-10-31
NZ513800A (en) 2001-09-28
HUP9903694A3 (en) 2002-10-28
DE69737631T3 (de) 2011-08-18
US20030134775A1 (en) 2003-07-17
RU2003103606A (ru) 2004-08-27
ES2286834T5 (es) 2011-01-31
EP0956865B1 (en) 2007-04-18
BG103246A (en) 2000-05-31
BG107195A (en) 2003-05-30
US6906061B2 (en) 2005-06-14
KR100595740B1 (ko) 2006-07-03
HUP9903694A2 (hu) 2000-03-28
IS4973A (is) 1999-02-11
DK0956865T4 (da) 2010-11-22
SI0956865T2 (sl) 2011-04-29
CZ46099A3 (cs) 1999-07-14
AU738620B2 (en) 2001-09-20
EP0956865B2 (en) 2010-08-18
ATE359822T1 (de) 2007-05-15
PT956865E (pt) 2007-07-30
DE69737631T2 (de) 2007-12-27
WO1998006433A1 (en) 1998-02-19
BR9711154A (pt) 1999-08-17
EP0956865A4 (en) 2001-05-16
HK1022436A1 (en) 2000-08-11
RU2206321C2 (ru) 2003-06-20
CZ301044B6 (cs) 2009-10-21
KR100576148B1 (ko) 2006-05-03
ES2286834T3 (es) 2007-12-01
NZ334613A (en) 2002-02-01
US6451825B1 (en) 2002-09-17
DK0956865T3 (da) 2007-09-03
EP0956865A1 (en) 1999-11-17
BG63991B1 (bg) 2003-09-30
AU3785197A (en) 1998-03-06
RU2003104284A (ru) 2004-08-27
NO990622L (no) 1999-04-12
DE69737631D1 (de) 2007-05-31
NO990622D0 (no) 1999-02-10
CN100389828C (zh) 2008-05-28
HU229864B1 (en) 2014-10-28
CA2263425A1 (en) 1998-02-19
PL331561A1 (en) 1999-07-19
BG63992B1 (bg) 2003-09-30
CA2263425C (en) 2008-09-30
KR20050055022A (ko) 2005-06-10
US6218410B1 (en) 2001-04-17
KR20000029918A (ko) 2000-05-25
US20020032148A1 (en) 2002-03-14
BG107645A (en) 2004-05-31

Similar Documents

Publication Publication Date Title
EE9900050A (et) Rho kinaasi inhibiitorit sisaldav farmatseutiline aine
EP1783139A3 (en) Human telomerase catalytic subunit
ATE383875T1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
CA2310888A1 (en) Monoclonal human natural antibodies
ITMI951359A0 (it) Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali
PT84841A (de) Ungesattigte fettsauren enthaltende zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaueren in biologischen systemen
HUP9901375A2 (hu) Antigénspecifikus immunszupressziós génterápiában alkalmazható új peptidek
ATE226447T1 (de) Anti-fas antikörper gegen rheumatische krankheiten
DE69627780D1 (de) Peptid das eine Immunantwort gegen menschlichen Magenkrebs induziert und Arzneimittel die es enthält zur Vorbeugung oder Behandlung von Magenkrebs
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
ATE184005T1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
CA2245425A1 (en) Neospora vaccine
EA199800417A1 (ru) Фармацевтическая композиция для лечения аутоиммунных заболеваний
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
CA2188816A1 (en) Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
NO980384L (no) Fremgangsmåte for fremstilling av fastdoseformer av svært lav-dose legemidler
DE69825395D1 (de) Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
EP1420776A4 (en) MEDICINES FOR TREATING BRAIN INJURIES AND METHODS OF USE THEREFOR
ATE205841T1 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
SE9800359D0 (sv) Pharmaceutical preparation and method for treatment, prevention and diagnosis of gastrooesophageal reflux disease
TH20326A (th) "สารผสมสำหรับเพิ่มความสามารถในการเรียนรู้"
TH25792A (th) สูตรผสมริโดเจรลขนาดต่ำ

Legal Events

Date Code Title Description
HC1A Change of owner name